Drug Trial Radar · NCT04687020
Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)
Last checked: Nov 20, 2026Latest source record: Oct 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
9
Actual
Start
Jun 10, 2021
Primary completion
Sep 2032
Study completion Oct 2032
Sponsor
- Lead sponsor
- NS Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The VILT-502 study is Non-interventional Study(United States)/Low-intervention Clinical Trial (Canada) of Viltolarsen administered intravenously once weekly for 10 years to boys with DMD who complete the NS-065/NCNP-01-202 study.
Conditions
- Duchenne Muscular Dystrophy
Interventions
ViltolarsenDrug
Received during weekly intravenous infusions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment related Adverse Events as assessed by CTCAE v4.0Time frame: baseline to up to 120 months of treatment
- Change in Time to Stand (TTSTAND)Time frame: baseline to up to 120 months of treatment
- Change in Time to Run/Walk 10 meters (TTRW)Time frame: baseline to up to 120 months of treatment
- Change in Performance of Upper Limb (PUL)Time frame: baseline to up to 120 months of treatment
- Loss of Ambulation (LOA)Time frame: baseline to up to 120 months of treatment
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
UC Davis
Sacramento, California
Lurie Children's Hospital
Chicago, Illinois
Duke University Medical Center
Durham, North Carolina
Children's Hospital of Richmond at VCU
Richmond, Virginia
Alberta Children's Hospital
Calgary, Alberta, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.